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Purpose: To examine the effects of genetic polymorphisms in cytochrome P450, subfamily 1, polypeptide 1 (C1P1B1)
on primary open-angle glaucoma (POAG).
Methods: A systematic literature search was performed, and random-effects meta-analyses were used to evaluate genetic
polymorphisms in CYP1B1 with POAG. A gene-based analysis was conducted to investigate the cumulative effects of
genetic polymorphisms in CYP1B1.
Results: A total of six studies from published papers were included in our analysis. Random-effects meta-analyses failed
to detect any significant association of POAG with genetic polymorphisms in CYP1B1, including rs180040, rs1056836,
rs10012, rs1056827, rs1056837, and rs2567206. The gene-based analysis indicated that the cumulative effect of genetic
polymorphisms in CYP1B1 is not associated with POAG (p>0.50).
Conclusions: We did not find any evidence of strong association of POAG with CYP1B1 genetic polymorphisms and
their cumulative effect.
Glaucoma  is  defined  as  a  group  of  heterogeneous,
complex  disorders  characterized  by  a  progressive  loss  of
retinal  ganglion  cells;  it  is  a  major  cause  of  irreversible
blindness [1,2]. Primary open-angle glaucoma (POAG) is the
most common form of glaucoma, leading to an estimated 3.3
million cases of bilateral blindness worldwide [3]. POAG is
defined by an open, normal appearing anterior chamber angle
and  raised  intraocular  pressure  (IOP),  with  no  other
underlying disease. The onset of the disease is not obvious to
the patient until there is appreciable and irreversible loss of
the field of vision.
POAG is a complex disease caused by multiple genetic
and environmental factors, as well as their interactions [4-8].
A  previous  study  estimated  that  72%  of  all  POAG  cases
exhibited an inherited or familial form of the disease, which
does not show a clear pattern of Mendelian inheritance [9].
Mutations,  polymorphisms,  and  copy  number  variations
(CNVs) could contribute to the pathogenesis of POAG. To
date, more than 20 genetic loci have been implicated in its
development  [10].  Linkage  analysis  has  identified  two
POAG-causing genes, myocilin (MYOC) [5] and optineurin
(OPTN)  [7].  More  than  70  MYOC  mutations  have  been
reported to contribute to the pathogenesis of POAG [10], and
OPTN mutations have been associated with normal tension
glaucoma (NTG) [7]. Variants in these two genes account for
about 5% of POAG in the population [7,11]. Previous studies
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also have reported the association of POAG with mutations in
WD  repeat  domain  36  (WDR36)  [12]  and  neurotrophin-4
(NTF4) [13,14]; however, their roles in the pathogenesis of
POAG is controversial [15]. CNVs are defined as insertions
or deletions of large segments of DNA, from 1 kb up to several
Mb; they have been found to contribute to many complex
disorders, such as autism [16,17], schizophrenia [18], and
Crohn’s disease [19]. A recent study identified 11 validated
CNVs  in  patients  with  POAG,  but  not  in  age-matched
controls,  suggesting  the  potential  role  that  the  CNV-
implemented genes might play in the pathogenesis of POAG.
Mutations  in  CYP1B1  (cytochrome  P450,  family  1,
subfamily  B,  polypeptide  1)  have  also  been  identified  in
POAG patients and may be suggested as a modifier of POAG
in carriers of MYOC mutations [20,21]. Most studies on the
effect of CYP1B1 on POAG have investigated only genetic
mutations in this gene [20,22-29]. Although a few studies have
evaluated the association of single-nucleotide polymorphisms
(SNPs) of CYP1B1 with PAOG, the results are conflicting
[22,30-34].
In this study, we conducted a systematic literature search
of  published  studies  examining  the  association  of  genetic
polymorphisms of CYP1B1 with POAG and conducted meta-
analyses of SNPs in this gene. POAG is a complex disorder,
and it is highly likely that individual SNPs may contribute
little to its onset and development. However, their cumulative
effects may be significant. Therefore, we conducted a gene-
based analysis to investigate the cumulative effects of the
genetic polymorphisms in CYP1B1 on POAG.
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Search strategy and study selection: In October 2011, we
conducted  an  extensive  literature  search  of  MEDLINE,
Cochrane  Library,  Web  of  Science,  and  Google  Scholar.
Search  terms  included  “primary  open  angle  glaucoma,”
“CYP1B1,”  “SNP,”  “polymorphism,”  and  “POAG.”  The
following inclusion criteria were used in the search: 1) studies
on  human  subjects;  2)  studies  on  POAG;  3)  reported
association (or have data available to calculate the association)
of genetic polymorphism of individual SNPs in CYP1B1 with
POAG; and 4) provided odds ratios and their variance (or data
to  calculate  the  variance)  or  genotype  frequency  among
participants with and without POAG. All potentially relevant
publications were retrieved and evaluated for inclusion. We
also hand-searched references of all relevant publications for
additional studies missed by the database search. Our search
was restricted to studies published in the English language.
Two  authors  (S.D.  and  J.Y.)  performed  the  search
independently. Disagreement over eligibility of a study was
resolved by the evaluation of a third reviewer (W.Y.) and
discussion until a consensus was reached.
Statistical analysis: We used odds ratio (OR) as a measure of
the association of the genetic polymorphisms in CYP1B1 with
POAG. ORs were used as provided in the papers or were
calculated  from  genotype  frequency  data,  and  they  were
logarithmically transformed to improve normality. Standard
errors  were  derived  from  the  confidence  intervals  (CI)
reported in each study. Random-effects models were used to
calculate ORs and their corresponding 95% CIs. The z-test
was used to calculate the p-value of the overall effect, and a
forest plot was used to present the calculated pooled ORs and
their 95% CIs. In the forest plot, each study was represented
by a square whose area was proportional to the weight of the
study. The weight of each study was determined by taking the
inverse of the variance of each study. The overall effect from
meta-analysis is represented by a diamond in the forest plot;
the  width  of  the  diamond  represents  the  95%  CI  for  the
estimated OR. We used Q statistics to assess between-study
heterogeneity.  Because  Q  statistics  are  underpowered,  we
considered studies to be homogeneous if p>0.1. Publication
bias was assessed visually using a funnel plot and tested with
Egger’s regression test.
To assess the overall association of CYP1B1 with POAG,
we conducted a gene-based analysis, using the reported p-
values  of  the  association  of  genetic  polymorphisms  in
CYP1B1 with POAG and the p-values from our meta-analysis.
This  association  was  assessed  using  four  popular  p-value
combination methods: Fisher’s method, the Simes method,
the  modified  inverse  normal  method,  and  the  truncated
product method (TPM). A detailed description of the four
methods has been published elsewhere [35]. We conducted
100,000  simulations  to  estimate  the  p-value  using  TPM,
Figure  1.  Flow  diagram  of  studies
included in the systematic review. Note:
Please  see  the  Methods  section  for
additional details.
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787because the p-values of the association of individual SNPs
within CYP1B1 with POAG are most likely to be dependent.
Meta-analysis was performed using Stata 11.2 (StataCorp
LP, College Station, TX). All other analyses were performed
using Matlab 7.10.0.499 (The MathWorks, Inc., Natick, MA).
RESULTS
Literature  search  and  eligible  studies:  A  flow  diagram
showing  the  selection  process  of  studies  included  in  our
analysis is shown in Figure 1. Our initial search, using our pre-
defined  search  strategy,  identified  a  total  of  31  potential
studies.  After  reviewing  each  abstract,  three  studies  were
excluded, because they either were irrelevant or were not
conducted on human subjects. The remaining 28 studies were
retrieved for more detailed review. An additional 23 studies
were  excluded  because  the  outcome  of  interest  was  not
POAG,  the  study  examined  mutations  instead  of  genetic
polymorphisms,  the  study  was  a  review,  or  there  was
insufficient data. A review of references for the remaining five
studies  identified  one  more  relevant  study.  A  total  of  six
studies from published papers met the eligibility criteria and
were included in our analyses [22,30-34].
All qualified studies were published after 2005, and they
had sample sizes ranging from 271 to 1,758 participants. The
reported prevalence of POAG ranged from 47% to 83% (Table
1). Of these six studies, five reported association results for
rs180040  and  rs1056836,  three  for  rs10012,  and  two  for
rs1056827, rs1056837, and rs2567206. These studies were
included in the corresponding meta-analysis for each of the
six SNPs. The combined study population included 3,294
participants in the meta-analysis of rs180040 and rs1056836,
930  in  rs10012,  and  571  in  rs1056827,  rs1056837,  and
rs2567206. In addition to these six SNPs, the association
between POAG and 14 other SNPs in CYP1B1 was reported
in  single  individual  studies  [22,30,32].  The  results  from
individual studies and our meta-analysis were used to conduct
our gene-based analysis.
Assessment of publication bias: Funnel plots and Egger’s test
were  used  to  assess  publication  bias  (Figure  2A-C).  No
publication  bias  was  detected  for  the  meta-analyses  of
rs180040 (t=0.22, 95% CI: −7.66–8.79; p=0.84), rs1856836
(t=-1.02, 95% CI: −13.26–6.83; p=0.38), or rs10012 (t=3.84,
95% CI: −8.89–16.60; p=0.16). Due to the limited number of
studies, publication bias could not be assessed for the meta-
analyses of rs1056827, rs1056837, and rs2567206.
Association  of  individual  SNPs  with  POAG:  Five  studies
provided results on the association of rs180040 with POAG.
Random-effects meta-analysis provided an estimated odds
ratio  of  1.18  (95%  CI:  0.60–2.32;  p=0.63),  indicating  no
significant association of the SNP with POAG (Figure 3A,
Table  2A).  There  was  significant  between-study
heterogeneity (Q=37.85, p<0.001).
Five  studies  provided  results  on  the  association  of
rs1056836  with  POAG.  Random-effects  meta-analysis
provided an estimated odds ratio of 0.67 (95% CI: 0.37–1.11;
p=0.19),  indicating  no  significant  association  with  POAG
(Figure 3B, Table 2B). There was significant between-study
heterogeneity (Q=58.63, p<0.001).
Three  studies  provided  results  on  the  association  of
rs10012 with POAG. Random-effects meta-analysis provided
an estimated odds ratio of 1.00 (95% CI: 0.78–1.28; p=0.99),
indicating no significant association with POAG (Figure 3C,
Table  2C).  There  was  no  between-study  heterogeneity
(Q=1.66, p=0.44).
Two  studies  provided  results  on  the  association  of
rs1056827  with  POAG.  Random-effects  meta-analysis
provided an estimated odds ratio of 1.18 (95% CI: 0.83–1.70;
p=0.36),  indicating  no  significant  association  with  POAG
(Table  2D).  There  was  no  between-study  heterogeneity
(Q=0.01, p=0.92).
Two  studies  provided  results  on  the  association  of
rs1056837  with  POAG.  Random-effects  meta-analysis
provided an estimated odds ratio of 0.83 (95% CI: 0.60–1.16;
p=0.28),  indicating  no  significant  association  with  POAG
(Table  2E).  There  was  no  between-study  heterogeneity
(Q=0.17, p=0.68).
Two  studies  provided  results  on  the  association  of
rs2567206  with  POAG.  Random-effects  meta-analysis
TABLE 1. BASIC CHARACTERISTICS OF ALL STUDIES.
Study Year of publication Study population Age Prevalence of POAG
[30] 2006 200 POAG patients and 100 controls in
India
mean age 52.4±19.3 67%
[31] 2008 264 POAG patients and 95 controls in
India
mean age 55.7±16.8 74%
[32] 2010 860 POAG patients and 898 controls in
Australia
mean age 70.7 49%
[33] 2010 405 POAG patients and 201 controls in
Hong Kong
mean age 57.8 and 69.8 for POAG patients
and controls, respectively
67%
[34] 2005 224 POAG patients and 47 controls in
France
- 83%
[22] 2010 339 POAG patients and 376 controls in
Germany
mean age 66.9±13.4 and 73.9±6.4 for POAG
patients and controls, respectively
47%
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788Figure 2. Begg’s funnel plots of random effects meta-analysis of the association of genetic polymorphisms in CYP1B1 with primary open-
angle glaucoma (POAG). The horizontal line in the figure represents the overall estimated log-transformed odds ratio. The two diagonal lines
represent the pseudo 95% confidence limits of the effect estimate. A: Funnel plot for random effects meta-analysis of rs180040 with POAG.
B: Funnel plot for random effects meta-analysis of rs1056836 with POAG. C: Funnel plot for random effects meta-analysis of rs10012 with
POAG.
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789Figure 3. Forest plots of estimates of odds ratios of the association of genetic polymorphisms in CYP1B1 with primary open-angle glaucoma
(POAG). Each study was represented by a square whose area was proportional to the weight of the study. The overall effect from meta-analysis
is represented by a diamond whose width represents the 95% CI for the estimated OR. A: Estimates of odds ratio of rs180040 in CYP1B1
with POAG. B: Estimates of odds ratio of rs1056836 in CYP1B1 with POAG. C: Estimates of odds ratio of rs10012 in CYP1B1 with POAG.
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790provided an estimated odds ratio of 1.12 (95% CI: 0.74–1.69;
p=0.60),  indicating  no  significant  association  with  POAG
(Table  2F).  There  was  no  between-study  heterogeneity
(Q=1.83, p=0.18).
In addition to these six SNPs, the association of POAG
with 14 other SNPs in C1P1B1 was reported in individual
studies. The results from these studies, together with the meta-
analysis results obtained from this study, are summarized in
Table 3.
Gene-based  analysis:  Using  the  p-values  obtained  from
association of individual SNPs with POAG, we performed a
gene-based association study to examine the cumulative effect
of these genetic polymorphisms on POAG. None of the four
methods indicated an association of CYP1B1 with POAG (all
p>0.5, Table 4).
DISCUSSION
In this paper, we conducted a systematic search and conducted
meta- and gene-based analyses of the genetic polymorphisms
in CYP1B1 with POAG. Our meta-analyses did not detect any
statistically significant associations between polymorphisms
of CYPIB1 and POAG. The gene-based analysis indicated that
there  is  no  significant  association  of  PAOG  with  the
TABLE 2. META-ANALYSIS OF THE ASSOCIATION OF SNPS WITH POAG.
Study Weights OR (95% CI) p-value
A. rs180040
[30] 21.26 0.82 (0.42–1.62) 0.57
[31] 23.20 0.81 (0.48–1.38) 0.43
[32] 26.60 0.96 (0.81–1.14) 0.62
[33] 4.16 0.39 (0.02–8.22) 0.55
[34] 24.78 3.48 (2.34–5.15) 5.89×10
-10
Total - 1.18 (0.60–2.32) 0.63
B.
rs1056836
[30] 19.20 0.81 (0.49–1.32) 0.39
[31] 19.61 0.17 (0.11–0.26) 4.31×10
-15
[32] 21.74 1.00 (0.88–1.15) 0.98
[33] 19.86 1.10 (0.72–1.68) 0.66
[34] 19.59 0.86 (0.55–1.36) 0.53
Total - 0.67 (0.37–1.22) 0.19
C. rs10012
[30] 26.13 1.20 (0.74–1.97) 0.46
[31] 51.61 0.85 (0.60–1.21) 0.37
[34] 22.26 1.16 (0.68–1.97) 0.59
Total - 1.00 (0.78–1.28) 0.99
D.
rs1056827
[30] 54.00 1.20 (0.74–1.97) 0.71
[34] 46.00 1.16 (0.68–1.97) 0.79
Total - 1.18 (0.83–1.70) 0.36
E.
rs1056837
[30] 45.88 0.77 (0.47–1.26) 0.30
[34] 54.12 0.89 (0.57–1.40) 0.61
Total - 0.83 (0.60–1.16) 0.28
F.
rs2567206
[30] 37.52 0.85 (0.50–1.46) 0.56
[34] 62.48 1.32 (0.94–1.83) 0.10
Total - 1.12 (0.74–1.69) 0.60
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791cumulative  effects  of  the  genetic  polymorphisms  in
CYP1B1. To the best of our knowledge, this is the first study
on the association of polymorphisms in CYP1B1 with POAG
through a meta- and gene-based approach.
Genetic factors play a critical role in predisposition to
POAG. However, the genetic pathophysiology of glaucoma
remains largely unknown, with mutations in known genes
accounting for less than 15% of the disease [29]. Two genes
(MYOC and OPTN) have been reported to show a causative
relationship with POAG [5,7]. Mutations of myocilin protein
could obstruct the outflow of the aqueous humor through the
trabecular meshwork, leading to a markedly elevated IOP.
Mice  with  myocilin  mutations  in  Tyr437His  have  shown
POAG symptoms, such as elevated IOP, RGC death, and
axonal degeneration in the optic nerve [36-38]. Optineurin
protein might play a role in the protection of the optic nerve
from tumor necrosis factor-mediated apoptosis, and mutations
in optineurin could lead to loss of function of this protein,
which could decrease the threshold for ganglion cell apoptosis
in patients with glaucoma [7].
Mutations  in  CYP1B1  also  have  been  reported  to  be
implicated in POAG. CYP1B1 (OMIM 601771) is located on
chromosome 2p21 at the GLC3A locus. Being a member of
the cytochrome p450 gene superfamily of monooxygenase, it
recently became known for its role in eye development during
embryogenesis [39]. Studies have shown that the frequency
of CYP1B1 mutations varies in patients across countries–5.0%
in Canada [40], 4.6% in France [41], 10.9% in Spain [21],
4.5% in Eastern India [30], and 10.8% in Southern India
[42]. Previous studies have indicated a minor involvement of
the mutations in CYP1B1 in the pathogenesis of juvenile open-
angle  glaucoma  (JOAG)  and  POAG  [20,24,26,28,29].  In
addition,  CYP1B1  mutations  have  been  suggested  to  be
associated with clinical features like optic disc cupping and
visual field loss [34]. One study showed that CYP1B1−/− mice
exhibited  structural  abnormalities  in  the  ocular  drainage
structures, similar to human primary congenital glaucoma
(PCG)  [43,44].  However,  the  exact  mechanism  by  which
CYP1B1 contributes to glaucoma remains unknown.
TABLE 3. ASSOCIATION OF INDIVIDUAL SNPS IN CYP1B1 WITH POAG.
SNP OR (95% CI) p
C1328G>C 1.06 (0.07–17.03) 0.97
C1394T>C 0.35 (0.01–8.69) 0.53
C1557G>C 0.66 (0.03–16.39) 0.80
C1572T>C 0.40 (0.02–8.31) 0.55
C1925T>C 1.29 (0.68–2.47) 0.43
C2016C>G 0.18 (0.01–3.23) 0.24
C503G>A 0.35 (0.01–8.69) 0.53
C685G>A 1.34 (0.52–3.42) 0.55
rs10175368 0.94 (0.81–1.09) 0.42
rs10916 1.13 (0.96–1.33) 0.14
rs162549 0.96 (0.82–1.13) 0.64
rs162556 1.13 (0.99–1.29) 0.07
rs162562 1.14 (0.97–1.34) 0.11
rs2617266 0.94 (0.53–1.68) 0.84
rs180040 1.18 (0.60–2.32) 0.63
rs1056836 0.67 (0.37–1.22) 0.19
rs10012 1.00 (0.78–1.28) 0.99
rs1056827 1.18 (0.83–1.70) 0.36
rs1056837 0.83 (0.60–1.16) 0.28
rs2567206 1.12 (0.74–1.69) 0.60
          Based on our meta-analyses and results reported in individual studies.
TABLE 4. GENE-BASED ANALYSIS OF GENETIC POLYMORPHISMS IN CYP1B1 WITH POAG.
Gene Fisher Simes Inverse TPM
CYP1B1 0.63 0.80 0.54 0.73
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792There  are  a  few  studies  on  the  effects  of  genetic
polymorphisms in CYP1B1 on POAG, with conflicting results
being reported [22,30-34]. One study revealed a significant
association  of  a  common  SNP,  L432V  (rs1056836),  in
CYP1B1 with POAG in the Indian population (OR=6.03, 95%
CI 3.86–9.40; p<0.001) [31]. Other studies failed to detect a
significant  association  [30,32-34].  Similarly,  the  study  by
Melki et al. [34] reported a significant association of another
common  SNP,  N453S  (rs180040),  with  POAG  in  French
patients  (OR=3.48,  95%  CI=2.34–5.15;  p<0.001),  but  no
significant association was found in other studies [30-33]. It
is unclear what factors contribute to the conflicting results
reported in these studies. We found significant heterogeneity
for the meta-analyses of the two SNPs (both p<0.001) and
speculate that different genetic structures among the different
populations might be an important factor accounting for the
disparate results. For example, the minor allele (G) frequency
of rs180040 in Caucasians is about 19% (Hapmap database),
while in the Chinese population it is reported to be 0.5% in
POAG  patients  and  0  in  controls  [33]  (0.4%  in  Hapmap
database). Of course, other factors, such as environment and
diet, might play roles in these differences as well.
There are certain limitations to this study. First, due to the
limited availability of published results, the number of studies
included in each meta-analysis is relatively small. We could
only perform meta-analysis for six SNPs in CYP1B1. The
association of the remaining 14 SNPs was based on the results
from single studies. We expect that as more studies become
available, a more accurate estimation of the relationship of
CYP1B1 with POAG will be obtained. Second, definition of
POAG was not consistent across the six studies for the meta-
and  gene-based  analyses  (Appendix  1).  Third,  although
efforts  have  been  made,  there  are  some  studies  that  used
different genetic models. One of our assumptions for the meta-
and  gene-based  analyses  is  that  different  genetic  models
should provide similar associations, which might not hold in
reality.
In  summary,  we  conducted  a  meta-  and  gene-based
analysis  of  the  association  of  POAG  with  genetic
polymorphisms  in  CYP1B1.  We  did  not  detect  any  SNP
showing significant association with POAG, and the gene-
based analysis indicated that, based on current evidence from
published studies, the cumulative effect of polymorphisms in
CYP1B1 is not significantly associated with POAG.
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795Appendix 1. Definition of POAG used by the six studies.
POAG: primary open-angle glaucoma; NTG: normal-
tension glaucoma; JOAG: juvenile open-angle glaucoma. To
access the data, click or select the words “Appendix 1.” This
will initiate the download of a compressed (pdf) archive that
contains the file.
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